Who
Daniel K. Spiegelman
Director
Company insider
Files Form 4 as: Director, vTv Therapeutics; Director, Maze Therapeutics; Director, Spruce Biosciences; Director, Kyverna Therapeutics; Director, Myriad Genetics; EVP, Chief Financial Officer, BioMarin Pharmaceutical; Director, Cascadian Therapeutics; Director, Relypsa.
In numbers
- Trades disclosed
- 300
- Buys
- 4
- Sells
- 48
- Bought
- $64K
- Sold
- $35.2M
- Companies
- 13
- Companies where not an officer
- 11
- First trade
- 3 Jan 2006
- Last trade
- 26 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 29 Jun 2026 | VTVT vTv Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $210K6,000 at $35.08 | filing |
| 26 Jun 2026filed 29 Jun 2026 | VTVT vTv Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $210K6,000 at $35.08 | filing |
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,700 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,700 at $0.00 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —458 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —458 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —88 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —88 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —400 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —400 | filing |
| 22 Sep 2025filed 24 Sep 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 22 Jul 2025filed 24 Jul 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | VTVT vTv Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $66K4,000 at $16.59 | filing |
| 29 May 2025filed 2 Jun 2025 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,351 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,634 at $0.00 | filing |
| 25 Jun 2024filed 27 Jun 2024 | VTVT vTv Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $103K6,000 at $17.22 | filing |
| 4 Jun 2024filed 4 Jun 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $84K3,788 at $22.05 | filing |
| 3 Jun 2024filed 4 Jun 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $83K3,788 at $22.04 | filing |
News
Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)MYGN · tickerreport.com · 20 Oct 2026Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing BusinessMYGN · investorideas.com · 20 Oct 2026FinancialContent - Myriad Genetics (MYGN) Stock Trades Up, Here Is WhyMYGN · financialcontent.com · 20 Oct 2026Critical Survey: XTL Biopharmaceuticals (NASDAQ:XTLB) & BioMarin Pharmaceutical (NASDAQ:BMRN)BMRN · tickerreport.com · 18 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by UBS GroupBMRN · tickerreport.com · 17 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, Barclays Analyst SaysBMRN · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Daniel K. Spiegelman; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.